Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.57 |
| ▸ | RPTOR | Q8N122 | 14/20 | 0.57 |
| ▸ | MLST8 | Q9BVC4 | 14/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.54 |
| ▸ | CSF1R | P07333 | 2/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.54 |
| ▸ | FLT4 | P35916 | 1/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.54 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154806 | 1.00 | MTOR (0.57) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL799974 | 1.00 | MTOR (0.57) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522569 | 1.00 | MTOR (0.57) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL154237 | 0.88 | MTOR (0.54) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL800589 | 0.88 | MTOR (0.54) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL154238 | 0.88 | MTOR (0.54) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL151020 | 0.86 | MTOR (0.58) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL800470 | 0.86 | MTOR (0.58) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL151019 | 0.86 | MTOR (0.58) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522255 | 0.86 | MTOR (0.58) | MTORRPTORMLST8PIK3CACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180369241-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | CELGENE CORP (US) | 2018-12-27 | — | — | US | claimed |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-04-06 | — | — | US | claimed |
| US-20170027932-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2017-02-02 | — | — | US | claimed |
| EP-2358718-B1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2017-01-18 | — | — | EP | claimed |
| EP-2493472-B1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARM LLC (US) | 2016-12-07 | — | — | EP | claimed |
| US-9415049-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-16 | — | — | US | claimed |
| EP-2740733-B1 | 3,4-Dihydropyrazino[2,3-b]pyrazin-2(1H)-one compounds as MTOR kinase inhibitors for oncology indications and diseases associated with the MTOR/P13K/AKT pathway | SIGNAL PHARM LLC (US) | 2015-12-30 | — | — | EP | claimed |
| US-9079900-B2 | Methods of synthesis and purification of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-07-14 | — | — | US | claimed |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-25 | — | — | US | claimed |
| US-20140155593-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-06-05 | — | — | US | claimed |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | claimed |
| US-8492381-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-07-23 | — | — | US | claimed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | claimed |
| US-20120071658-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | PERRIN-NINKOVIC SOPHIE (US) | 2012-03-22 | — | — | US | claimed |
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | claimed |
| US-20120028972-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | SIGNAL PHARMACEUTICALS, LLC | 2012-02-02 | — | — | US | claimed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | claimed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | claimed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | claimed |
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | SIGNAL PHARM LLC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4218763-A1 | 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-B]PYRAZIN-2(1H)-ONE FOR TREATING GLIOBLASTOMA MULTIFORME | Signal Pharmaceuticals, LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3660020-B1 | PROCESS FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2023-04-20 | — | — | US | disclosed |
| EP-2986299-B1 | 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-B]PYRAZIN-2(1H)-ONE FOR TREATING GLIOBLASTOMA MULTIFORME | SIGNAL PHARM LLC (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-3659599-B1 | 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-B]PYRAZIN-2(1H)-ONE FOR USE IN THE TREATMENT OF GLIOBLASTOMA MULTIFORME | SIGNAL PHARM LLC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-11292796-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3466423-B1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3131550-B1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY WITH A HISTONE DEACETYLASE INHIBITOR | SIGNAL PHARM LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200262840-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200262840-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3131552-B1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10683298-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683298-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3659599-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660020-A1 | PROCESS FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3103803-B1 | INTERMEDIATES FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2020-03-11 | — | — | EP | disclosed |
| EP-3091021-B1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARM LLC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-10391092-B2 | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| EP-2768500-B1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2817029-B1 | METHODS FOR TREATING NON-SMALL CELL LUNG CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3466423-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20190077806-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190077806-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2019-03-14 | — | — | US | disclosed |
| US-10183019-B2 | Treatment of cancer with dihydropyrazino-pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-10167290-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-10167290-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180185361-A1 | METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2018-07-05 | — | — | US | disclosed |
| US-9980963-B2 | Treatment of cancer with dihydropyrazino-pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2825169-B1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2825168-B1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2825170-B1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9937169-B2 | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2909627-B1 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | SIGNAL PHARM LLC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-2825171-B1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170342080-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342080-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342080-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2017-11-30 | — | — | US | disclosed |
| US-9771371-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771371-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170182044-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | SIGNAL PHARM LLC (US) | 2017-06-29 | — | — | US | disclosed |
| EP-2740732-B1 | MTOR kinase inhibitors for oncology indications and diseases associated with the MTOR/P13K/AKT pathway | SIGNAL PHARM LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9630966-B2 | Treatment of cancer with dihydropyrazino-pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-04-06 | — | — | US | disclosed |
| US-20170065583-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | SIGNAL PHARM LLC (US) | 2017-03-09 | — | — | US | disclosed |
| EP-3131550-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | Signal Pharmaceuticals, LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-3131552-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | Signal Pharmaceuticals, LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9555033-B2 | Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2358718-B1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-3103803-A1 | INTERMEDIATES FOR THE SYNTHESIS OF MTOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2493472-B1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARM LLC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9505764-B2 | Treatment of cancer with dihydropyrazino-pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-11-29 | — | — | US | disclosed |
| US-9493466-B2 | Treatment of cancer with TOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3091021-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9415049-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| EP-3052093-A1 | A TOR KINASE INHIBITOR IN THE PREVENTION OR TREATMENT OF CANCER CHARACTERIZED BY GENE MUTATIONS | Signal Pharmaceuticals, LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2992878-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2986320-A1 | COMBINATION THERAPY COMPRISING A DIHYDROPYRAZINO-PYRAZINE COMPOUND AND AN ANDROGEN RECEPTOR ANTAGONIST FOR TREATING PROSTATE CANCER | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2986298-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2986297-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2986318-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND AN IMID COMPOUND FOR TREATING CANCER | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2986299-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2986321-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A CYTIDINE ANALOG FOR TREATING CANCER | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2986322-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A 5-SUBSTITUTED QUINAZOLINONE COMPOUND FOR TREATING CANCER | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-2986319-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND N-(3-(5-FLUORO-2-(4-(2-METHOXYETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)PHENYL)ACRYLAMIDE FOR TREATING CANCER | Signal Pharmaceuticals, LLC (US) | 2016-02-24 | — | — | EP | disclosed |
| WO-2016025651-A1 | COMBINATIONS OF AN ERK INHIBITOR AND A TOR INHIBITOR AND RELATED METHODS | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160024101-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160024101-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARM LLC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2961408-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2740733-B1 | 3,4-Dihydropyrazino[2,3-b]pyrazin-2(1H)-one compounds as MTOR kinase inhibitors for oncology indications and diseases associated with the MTOR/P13K/AKT pathway | SIGNAL PHARM LLC (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9193692-B2 | Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193692-B2 | Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193692-B2 | Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-11-24 | — | — | US | disclosed |
| WO-2015160868-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015160869-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-2909627-A2 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | Signal Pharmaceuticals, LLC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2908814-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9079900-B2 | Methods of synthesis and purification of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2015051251-A1 | A TOR KINASE INHIBITOR IN THE PREVENTION OR TREATMENT OF CANCER CHARACTERIZED BY GENE MUTATIONS | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-04-09 | — | — | WO | disclosed |
| US-20150051397-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS LLC | 2015-02-19 | — | — | US | disclosed |
| US-20150051397-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS LLC | 2015-02-19 | — | — | US | disclosed |
| US-20150051397-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS LLC | 2015-02-19 | — | — | US | disclosed |
| EP-2825171-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825169-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825170-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825168-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2817029-A1 | METHODS FOR TREATING NON- SMALL CELL LUNG CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | Signal Pharmaceuticals, LLC (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2014062878-A9 | TREATMENT OF PROSTATE CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-12-18 | — | — | WO | disclosed |
| US-8907087-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8907087-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8907087-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| WO-2014172436-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A 5-SUBSTITUTED QUINAZOLINONE COMPOUND FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014172431-A1 | COMBINATION THERAPY COMPRISING A DIHYDROPYRAZINO-PYRAZINE COMPOUND AND AN ANDROGEN RECEPTOR ANTAGONIST FOR TREATING PROSTATE CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014172426-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014172425-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315900-A1 | METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2014172429-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND AN IMID COMPOUND FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014172432-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A CYTIDINE ANALOG FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014172430-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND N-(3-(5-FLUORO-2-(4-(2-METHOXYETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)PHENYL)ACRYLAMIDE FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014172424-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140314674-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140314673-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315907-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2014134240-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-2768500-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| EP-2739751-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | Signal Pharmaceuticals, LLC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2740732-A1 | MTOR kinase inhibitors for oncology indications and diseases associated with the MTOR/P13K/AKT pathway | Signal Pharmaceuticals, LLC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2740733-A1 | MTOR kinase inhibitors for oncology indications and diseases associated with the MTOR/P13K/AKT pathway | Signal Pharmaceuticals, LLC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20140155593-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2014066125-A2 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014062878-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-04-24 | — | — | WO | disclosed |
| US-20140113904-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130289271-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289271-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130289271-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-10-31 | — | — | US | disclosed |
| US-8569494-B2 | Methods of synthesis and purification of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2013138560-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138557-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138553-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138556-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130245028-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245026-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245029-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245027-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013126636-A1 | METHODS FOR TREATING NON- SMALL CELL LUNG CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | WO | disclosed |
| US-8507492-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-13 | — | — | US | disclosed |
| US-8492381-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492381-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492381-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130102613-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013059396-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013019927-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-2531194-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120071658-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | PERRIN-NINKOVIC SOPHIE (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | PERRIN-NINKOVIC SOPHIE (US) | 2012-03-08 | — | — | US | disclosed |
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20120028972-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | SIGNAL PHARMACEUTICALS, LLC | 2012-02-02 | — | — | US | disclosed |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-20 | — | — | US | disclosed |
| WO-2011097333-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (39 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051397-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 81/4885 |
| US-10167290-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | MTOR, RICTOR, RPS6KA2 | MTOR 1/4885RPTOR 30/4885MLST8 266/4885 |
| US-20130245027-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, BRCA1 | MTOR 1/4885RPTOR 6/4885MLST8 138/4885 |
| US-20140315900-A1 | METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY | AR, NR5A2, GNRHR | MTOR 1333/4885RPTOR 3021/4885MLST8 3560/4885 |
| US-10683298-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | MTOR, RICTOR, PDK1 | MTOR 1/4885RPTOR 5/4885MLST8 254/4885 |
| US-20110257167-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | STK11, STK16, STK10 | MTOR 11/4885RPTOR 30/4885MLST8 72/4885 |
| US-20180369241-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | DKK1, WNT1, DCK | MTOR 403/4885RPTOR 2148/4885MLST8 3030/4885 |
| US-20230119470-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 81/4885 |
| US-20230338370-A1 | Treatment of Cancer with TOR Kinase Inhibitors | MTOR, TTK, BRCA1 | MTOR 1/4885RPTOR 6/4885MLST8 138/4885 |
| US-20170027932-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | MTOR 1/4885RPTOR 6/4885MLST8 93/4885 |
| US-20130245026-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, CHEK2, CHEK1 | MTOR 1/4885RPTOR 7/4885MLST8 204/4885 |
| US-20120028972-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | MTOR, RPTOR, ULK1 | MTOR 1/4885RPTOR 2/4885MLST8 35/4885 |
| US-11292796-B2 | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 253/4885 |
| US-20120071658-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 78/4885 |
| US-10183019-B2 | Treatment of cancer with dihydropyrazino-pyrazines | MGMT, DNMT1, TPMT | MTOR 995/4885RPTOR 2545/4885MLST8 3944/4885 |
| US-20200262840-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 81/4885 |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 33/4885 |
| US-20140314674-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | MGMT, DNMT1, TPMT | MTOR 995/4885RPTOR 2545/4885MLST8 3944/4885 |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885RPTOR 478/4885MLST8 2577/4885 |
| US-20140315907-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | THPO, TP53, DPYD | MTOR 3334/4885RPTOR 4581/4885MLST8 4034/4885 |
| US-10391092-B2 | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy | AR, NR5A2, GNRHR | MTOR 1333/4885RPTOR 3021/4885MLST8 3560/4885 |
| US-20130289271-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 81/4885 |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885RPTOR 478/4885MLST8 2577/4885 |
| US-20170182044-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | MGMT, DNMT1, TPMT | MTOR 995/4885RPTOR 2545/4885MLST8 3944/4885 |
| US-20130158023-A1 | IDENTIFICATION OF GENE EXPRESSION AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | STK16, STK10, STK11 | MTOR 25/4885RPTOR 32/4885MLST8 79/4885 |
| US-20170065583-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | THPO, TP53, DPYD | MTOR 3334/4885RPTOR 4581/4885MLST8 4034/4885 |
| US-20130102613-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | MTOR 1/4885RPTOR 6/4885MLST8 93/4885 |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MTOR 3624/4885RPTOR 3916/4885MLST8 1475/4885 |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MTOR 3624/4885RPTOR 3916/4885MLST8 1475/4885 |
| US-20130245029-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | EWSR1, ELF3, MTOR | MTOR 3/4885RPTOR 12/4885MLST8 222/4885 |
| US-20160024101-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 81/4885 |
| US-20140314673-A1 | TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES | TOP2A, DNAH12, DDX21 | MTOR 4299/4885RPTOR 4702/4885MLST8 4516/4885 |
| US-20130245028-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | ELF3, ERG, MTOR | MTOR 3/4885RPTOR 7/4885MLST8 151/4885 |
| US-20140113904-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, TNNI3K | MTOR 1/4885RPTOR 6/4885MLST8 158/4885 |
| US-20180185361-A1 | METHODS FOR TREATING CANCER USING DIHYDROPYRAZINO-PYRAZINE COMPOUND COMBINATION THERAPY | AR, NR5A2, GNRHR | MTOR 1333/4885RPTOR 3021/4885MLST8 3560/4885 |
| US-20170342080-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 81/4885 |
| US-20140155593-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885RPTOR 478/4885MLST8 2577/4885 |
| US-20120059164-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITOR FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 78/4885 |
| US-20190077806-A1 | PYRAZINO[2,3-b]PYRAZINE mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.